CanBas Co. Ltd. | Income Statement

Fiscal year is July-June. All values JPY Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
-
60,958.00
105,243.00
109,852.00
110,000.00
Cost of Goods Sold (COGS) incl. D&A
14,726.00
12,579.00
-
-
-
Gross Income
14,726.00
48,379.00
-
-
-
SG&A Expense
469,088.00
331,921.00
472,298.00
479,248.00
649,456.00
EBIT
483,814.00
283,542.00
399,115.00
406,825.00
539,456.00
Unusual Expense
105,210.00
-
-
17,594.00
16,254.00
Non Operating Income/Expense
4,616.00
17,735.00
14,805.00
5,958.00
7,922.00
Interest Expense
1,118.00
-
-
-
-
Pretax Income
375,019.00
265,714.00
413,739.00
418,248.00
530,837.00
Income Tax
1,250.00
1,250.00
1,250.00
1,250.00
1,250.00
Consolidated Net Income
376,269.00
266,964.00
414,989.00
419,498.00
532,087.00
Net Income
376,269.00
266,964.00
414,989.00
419,498.00
532,087.00
Net Income After Extraordinaries
376,269.00
266,964.00
414,989.00
419,498.00
532,087.00
Net Income Available to Common
376,269.00
266,964.00
414,989.00
419,498.00
532,087.00
EPS (Basic)
101.46
62.51
85.78
83.38
96.70
Basic Shares Outstanding
3,708.70
4,270.90
4,838.00
5,031.40
5,502.30
EPS (Diluted)
101.46
62.51
85.78
83.38
96.70
Diluted Shares Outstanding
3,708.70
4,270.90
4,838.00
5,031.40
5,502.30
EBITDA
469,088.00
270,963.00
387,832.00
400,109.00
539,456.00
Other Operating Expense
-
-
20,777.00
30,713.00
-
Non-Operating Interest Income
87.00
93.00
181.00
214.00
288.00

About CanBas Co.

View Profile
Address
2-2-1 Otemachi
Numazu Shizuoka 410
Japan
Employees -
Website http://www.canbas.co.jp
Updated 07/08/2019
CanBas Co., Ltd. engages in pharmaceutical business. It focuses on the research and development of anti-cancer agent, drugs, and technologies which has minor impact on normal cell. Its technologies include drugs for the G2 check point and a screening system to find selective abrogates of the G2 check point.